Report on the Relative Efficacy of Oral Cancer Therapy for Medicare Beneficiaries Versus Currently Covered Therapy: Part 2, Imatinib for Gastrointestinal Stromal Tumors (GIST)

摘要

CMS has requested an assessment of the efficacy of selected oral cancer therapies included in the demonstration relative to drugs currently covered under Medicare Part B. This assessment will provide information that will be used to evaluate the likely effects of the demonstration on patient outcomes and may also provide underlying information to be used for cost-effectiveness analyses that will be completed by CMS. The scope of the assessment will be limited to the following demonstration drugs and conditions: Imatinib for treatment of chronic myeloid leukemia; Imatinib for treatment of gastrointestinal stromal cancer; Gefitinib for treatment of non-small cell lung cancer; and Thalidomide for treatment of multiple myeloma. This report is responsive to the second item: an assessment of imatinib for the treatment of gastrointestinal stromal tumors (GISTs).